Table 1 Clinical characteristics of study participants.
From: ZNF542P is a pseudogene associated with LDL response to simvastatin treatment
European American | African American | |||
|---|---|---|---|---|
High | Low | High | Low | |
N | 25 | 25 | 12 | 14 |
Men | 44% | 60% | 50% | 50% |
Smoker (%) | 4.0% | 8.0% | 8.3% | 14.3% |
Age (yrs) | 51.9 ± 14.6 | 54.5 ± 8.5 | 54.2 ± 7.8 | 51.7 ± 12.8 |
Before treatment LDLC level (mg/dl) | 132 ± 36 | 126 ± 26 | 129 ± 28 | 113 ± 32 |
LDLC percent change after statin treatment (%) | −59.1 ± 3.9% | −22.2 ± 8.0% | −57.5 ± 3.2% | −21.5 ± 6.5% |
LDLC level change after statin treatment (mg/dl) | −78.5 ± 23.0 | −28.2 ± 11.7 | −74.3 ± 16.9 | −24.3 ± 10.6 |
